Novartis: new positive CHMP opinion for Cosentyx
(CercleFinance.com) - Novartis announced on Friday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency on its application for marketing authorisation for a paediatric version of Cosentyx, its treatment for psoriasis.
In April the CHMP already recommended that Cosentyx be approved for the treatment of adult patients with active non-radiographic axial spondyloarthritis, a disease characterised by chronic inflammatory back pain.
Novartis says it is seeking approval of Cosentyx, a new type of immunosuppressant, in 10 different indications over the next 10 years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.